CTIS2023-508207-21-00招募中1 期
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered inCombination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 MonoclonalAntibody) in Advanced Malignant Tumors - CA224-048
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 325
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1, -Available tumor tissue for biomarker analysis, - Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
排除标准
- •- Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease, - Participants with a history of interstitial lung disease (ILD) /pneumonitis, - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before treatment assignment and the participant has no evidence of disease). Participants with history of prior early stage basal/squamous cell skin cancer or noninvasive or in situ cancers that have undergone definitive treatment at any time are also eligible
研究者
相似试验
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Malignant TumorsMedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2018-000058-22-ESBristol-Myers Squibb International Corporation184
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Malignant TumorsMedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2018-000058-22-GBBristol-Myers Squibb International Corporation184
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Malignant TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2018-000058-22-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO184
已完成
1 期
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsAdvanced Solid TumorsNCT05134948Bristol-Myers Squibb24
已完成
1 期
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced CancerNCT03459222Bristol-Myers Squibb229